🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

15 recruiting trials

for Cutaneous Basal Cell Carcinoma

Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC NCT05741073n/a1 site📍 Brussels EuMelaReg gGmbH Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors NCT04068155NA2 sites📍 Grenoble📍 Lyon Alpha Tau Medical LTD. · Tests: DaRT- Diffusing Alpha-emitters Radiation Therapy Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study NCT07215988n/a1 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Non-Interventional Study A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors NCT07600476Phase 13 sites📍 Munich📍 Würzburg📍 Münster Kupando GmbH · Tests: KUP-101A French National Database of Rare Dermatological Cancers NCT03210935n/a34 sites📍 Dijon📍 Le Mans📍 Pierre-Bénite University Hospital, Lille A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: MQ719, Pembrolizumab Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma NCT07251413Phase 1, Phase 24 sites📍 Barcelona📍 Barcelona📍 Madrid Instituto Oncológico Dr Rosell · Tests: cemiplimab, Topical imiquimod Personalised Immunotherapy Platform NCT06536257n/a3 sites📍 Sydney📍 Sydney📍 Sydney Melanoma Institute Australia · Tests: Predictive model L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) NCT07227350Phase 218 sites📍 Tampa📍 Atlanta📍 Durham Philogen S.p.A. · Tests: L19IL2, L19TNF, L19IL2/L19TNF L19IL2/TNF in Patients With Basal Cell Carcinoma NCT07227870Phase 218 sites📍 Tampa📍 Atlanta📍 New York Philogen S.p.A. · Tests: L19IL2/L19TNF A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients NCT07286318EARLY Phase 12 sites📍 Pittsburgh📍 Pittsburgh Marissa Lobl · Tests: Topical niacinamide 5% cream, Sunscreen Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia. NCT03889899NA1 site📍 Haifa Alpha Tau Medical LTD. · Tests: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer NCT05896839Phase 1, Phase 226 sites📍 La Jolla📍 Los Angeles📍 Los Angeles National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Kidney Biopsy A Beta-only IL-2 ImmunoTherapY Study NCT05086692Phase 1, Phase 228 sites📍 San Diego📍 San Francisco📍 Santa Monica Medicenna Therapeutics, Inc. · Tests: MDNA11, Pembrolizumab (KEYTRUDA®) Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia NCT04534127NA1 site📍 Jerusalem Alpha Tau Medical LTD. · Tests: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy